Early PSA decline as a predictor of progression in patients with metastatic castration-naïve prostate cancer (mCNPC) treated with abiraterone acetate and prednisone (AA/P).

Pedro C. Barata,Iris Yeong Fung Sheng,Jaleh Fallah,Ruby Gupta,Hong Li,Kimberly D Allman,Allison Martin,Moshe Chaim Ornstein,Timothy D. Gilligan,Brian I. Rini,Jorge A. Garcia

Early PSA decline as a predictor of progression in patients with metastatic castration-naïve prostate cancer (mCNPC) treated with abiraterone acetate and prednisone (AA/P).

2020

Pedro C. Barata
Iris Yeong Fung Sheng
Jaleh Fallah
Ruby Gupta
Hong Li
Kimberly D Allman
Allison Martin
Moshe Chaim Ornstein
Timothy D. Gilligan
Brian I. Rini
Jorge A. Garcia

e17542Background: Treatment intensification with androgen deprivation therapy (ADT) plus AA/P is a standard of care in patients with metastatic castration naive prostate cancer (mCNPC). Despite ini...

Keywords:

Urology
Abiraterone acetate
in patient
Prostate cancer
Castration
Pathology
Prednisone
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations